Atossa Therapeutics, Inc. Short Interest Declines by 6.8% in November

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) experienced a notable decrease in short interest during the month of November. By November 30th, the short interest stood at 11,600,000 shares. This marks a decline of 6.8% compared to the previous total of 12,450,000 shares reported on November 15th. With an average daily trading volume of 628,500 shares, the current days-to-cover ratio is 18.5 days.

Atossa Therapeutics Stock Performance

On Monday, NASDAQ ATOS opened at $1.12 per share. The stock has seen a year's range between a low of $0.70 and a high of $2.31. Currently, the stock has a 50-day moving average price of $1.35 and a 200-day moving average price of $1.33. Atossa Therapeutics holds a market capitalization of $140.90 million, with a price-to-earnings ratio of -5.09 and a beta value of 1.21.

Analyst Opinions on Atossa Therapeutics

Various brokerages have recently expressed their views on Atossa Therapeutics. On November 18th, StockNews.com downgraded the stock from a "hold" rating to a "sell" rating. On the other hand, Ascendiant Capital Markets increased their price target from $6.50 to $7.00, giving the stock a "buy" rating in a note dated December 9th. Additionally, HC Wainwright reiterated a "buy" rating and set the price target at $7.00.

Institutional Investor Activity

Several institutional investors have adjusted their positions in Atossa Therapeutics recently. In the third quarter, Intech Investment Management LLC made a new investment in the company, valued at approximately $29,000. XTX Topco Ltd also purchased a new stake during the second quarter valued at $29,000. In the first quarter, Cetera Advisors LLC acquired shares worth $72,000. Furthermore, SG Americas Securities LLC increased its holdings in the third quarter by 254.3%, now owning 41,849 shares worth about $64,000. The Manufacturers Life Insurance Company also acquired a $75,000 stake in the third quarter. Currently, institutional investors and hedge funds hold 12.74% of Atossa's stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on creating treatments for unmet medical needs in women's oncology, particularly breast cancer. The company's leading drug candidate is oral (Z)-endoxifen, a metabolite of tamoxifen, which is currently undergoing Phase II clinical trials aimed at treating and preventing breast cancer.

Atossa, Therapeutics, Stocks